Sandbox:farnaz: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) |
||
| Line 14: | Line 14: | ||
=== Type 2: === | === Type 2: === | ||
The primary therapy for MS may include: | The primary therapy for MS may include:<ref name="pmid25095894">{{cite journal| author=Kamm CP, Uitdehaag BM, Polman CH| title=Multiple sclerosis: current knowledge and future outlook. | journal=Eur Neurol | year= 2014 | volume= 72 | issue= 3-4 | pages= 132-41 | pmid=25095894 | doi=10.1159/000360528 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25095894 }} </ref> | ||
*B-interferon | *B-interferon | ||
*Teleflunomide | *Teleflunomide | ||
Revision as of 15:46, 26 January 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farnaz Khalighinejad, MD [2]
Overview
MS is known as multiple sclerosis.
Multiple Sclerosis
ajksfshvanivlk
Type 1:
asdad
Type 2:
The primary therapy for MS may include:[1]
- B-interferon
- Teleflunomide
| Cause | Symptom | Diagnosis | Treatment |
|---|---|---|---|
| 1 | |||
| 2 | |||
| 3 |
- ↑ Kamm CP, Uitdehaag BM, Polman CH (2014). "Multiple sclerosis: current knowledge and future outlook". Eur Neurol. 72 (3–4): 132–41. doi:10.1159/000360528. PMID 25095894.